致密乳腺且钼靶阴性女性的补充乳腺癌筛查:系统综述与荟萃分析
该系统综述与荟萃分析比较了平均或中等风险、致密乳腺且钼靶阴性的女性中常用补充筛查方式的临床结局。MRI在增量癌症检出率上优于其他补充方式,其余方式间无显著差异。
要点
- 致密乳腺且钼靶阴性时,MRI的增量癌症检出率最高。
- MRI在浸润性癌和原位癌检出率上均优于其他补充方式。
- 除MRI外,其他补充方式间各项指标无显著差异。
核心结论
- 汇总数据显示,在平均或中等风险、致密乳腺且钼靶阴性的女性中,MRI是最佳的补充筛查方式。
研究设计与样本
- 系统综述与荟萃分析,检索截至2020年3月12日,纳入随机对照试验和前瞻性观察研究。
- 采用随机效应荟萃分析和双侧荟萃回归比较各补充影像方式的指标。
诊断标准与关键数值
- MRI增量癌症检出率为每1000次筛查1.52例(95%CI:0.74,2.33;P < .001)。
- MRI增量浸润性癌检出率为每1000次筛查1.31例(95%CI:0.57,2.06;P < .001)。
- MRI原位癌检出率为每1000次筛查1.91例(95%CI:0.10,3.72;P < .04)。
- MRI与其他补充方式在召回阳性预测值(PPV1)和活检阳性预测值(PPV3)上无差异。
临床应用与阅片要点
- 对致密乳腺且钼靶阴性的平均或中等风险女性,可考虑MRI作为补充筛查以提高癌症检出。
- 除MRI外,数字乳腺断层合成、手持超声、自动乳腺超声间未见显著差异。
局限性
- 研究数量有限,无法评估间期癌指标。
- 仅纳入随机对照试验和前瞻性观察研究,可能遗漏其他设计的研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background The best supplemental breast cancer screening modality in women at average risk or intermediate risk for breast cancer with dense breast and negative mammogram remains to be determined. Purpose To conduct systematic review and meta-analysis comparing clinical outcomes of the most common available supplemental screening modalities in women at average risk or intermediate risk for breast cancer in patients with dense breasts and mammography with negative findings. Materials and Methods A comprehensive search was conducted until March 12, 2020, in Medline, Epub Ahead of Print and In-Process and Other Non-Indexed Citations; Embase Classic and Embase; Cochrane Central Register of Controlled Trials; and Cochrane Database of Systematic Reviews, for Randomized Controlled Trials and Prospective Observational Studies. Incremental cancer detection rate (CDR); positive predictive value of recall (PPV1); positive predictive value of biopsies performed (PPV3); and interval CDRs of supplemental imaging modalities, digital breast tomosynthesis, handheld US, automated breast US, and MRI in non-high-risk patients with dense breasts and mammography negative for cancer were reviewed. Data metrics and risk of bias were assessed. Random-effects meta-analysis and two-sided metaregression analyses comparing each imaging modality metrics were performed (PROSPERO; CRD42018080402). Results Twenty-two studies reporting 261 233 screened patients were included. Of 132 166 screened patients with dense breast and mammography negative for cancer who met inclusion criteria, a total of 541 cancers missed at mammography were detected with these supplemental modalities. Metaregression models showed that MRI was superior to other supplemental modalities in CDR (incremental CDR, 1.52 per 1000 screenings; 95% CI: 0.74, 2.33; P < .001), including invasive CDR (invasive CDR, 1.31 per 1000 screenings; 95% CI: 0.57, 2.06; P < .001), and in situ disease (rate of ductal carcinoma in situ, 1.91 per 1000 screenings; 95% CI: 0.10, 3.72; P < .04). No differences in PPV1 and PPV3 were identified. The limited number of studies prevented assessment of interval cancer metrics. Excluding MRI, no statistically significant difference in any metrics were identified among the remaining imaging modalities. Conclusion The pooled data showed that MRI was the best supplemental imaging modality in women at average risk or intermediate risk for breast cancer with dense breasts and mammography negative for cancer. © RSNA, 2023 Supplemental material is available for this article. See also the editorial by Hooley and Butler in this issue.
引用
- Hussein, Abbas, Keshavarzi, et al. Supplemental Breast Cancer Screening in Women with Dense Breasts and Negative Mammography: A Systematic Review and Meta-Analysis. Radiology. 2023. PMID: 36719288. doi:10.1148/radiol.221785
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。